Literature DB >> 12763411

Reduction in serum pepsinogen I after Roux-en-Y gastric bypass.

Magnus Sundbom1, Erik Mårdh, Sven Mårdh, Margareta Ohrvall, Sven Gustavsson.   

Abstract

The excluded stomach after Roux-en-Y gastric bypass (RYGBP) cannot be readily examined by endoscopy for obvious anatomic reasons. Thus it is difficult to monitor possible changes in the gastric mucosa. However, the type and severity of gastritis can now be assessed by a combination of serologic tests: pepsinogen I and antibodies to Helicobacter pylori and H,K-ATPase. Morbidly obese patients were examined before and 1 to 4 years after surgery. A group of 34 patients (mean age 39 years, BMI 44 kg/m(2)) underwent RYGBP; another group of 30 patients (mean age 42 years, BMI 44 kg/m(2)) had simple gastric restriction and served as control subjects. All patients, except one in the control group, had normal titers of pepsinogen I before surgery. One year after RYGBP, pepsinogen I levels were significantly reduced, as compared to the control group (P<0.0001), and remained low throughout the study. The control group had stable pepsinogen I levels. In both groups, few patients had increased titers of H. pylori or H,K-ATPase antibodies, but these abnormalities remained unchanged. Low pepsinogen I levels, similar to those we observed in our RYGBP patients, have been linked to chronic atrophic gastritis. However, the absence of food stimulation in the excluded stomach could also be a reason for the low pepsinogen I levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763411     DOI: 10.1016/s1091-255x(03)00063-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

1.  Bleeding from the bypassed stomach following gastric bypass.

Authors:  K J Printen; J LeFavre; J Alden
Journal:  Surg Gynecol Obstet       Date:  1983-01

2.  Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in helicobacter pylori-positive gastric ulcer after eradication of infection.

Authors:  T Ohkusa; I Takashimizu; K Fujiki; A Araki; K Honda; K Shimoi; T Sakurazawa; T Horiuchi; S Suzuki; K Ariake; K Ishii
Journal:  J Clin Gastroenterol       Date:  1997-07       Impact factor: 3.062

3.  Gastritis after gastric bypass surgery.

Authors:  H B McCarthy; R D Rucker; E K Chan; W M Rupp; D Snover; R L Goodale; H Buchwald
Journal:  Surgery       Date:  1985-07       Impact factor: 3.982

Review 4.  Long-term Helicobacter pylori infection and the development of atrophic gastritis and gastric cancer in Japan.

Authors:  Shin'ichi Takahashi
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

5.  Serum pepsinogen in screening for gastric cancer.

Authors:  A Kodoi; M Yoshihara; K Sumii; K Haruma; G Kajiyama
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

6.  Elevated serum pepsinogen I and II levels differ as risk factors for duodenal ulcer and gastric ulcer.

Authors:  I M Samloff; G N Stemmermann; L K Heilbrun; A Nomura
Journal:  Gastroenterology       Date:  1986-03       Impact factor: 22.682

7.  Serum antibodies to H+,K+-ATPase, serum pepsinogen A and Helicobacter pylori in relation to gastric mucosa morphology in patients with low or low-normal concentrations of serum cobalamins.

Authors:  A Lindgren; P Burman; A F Kilander; O Nilsson; G Lindstedt
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-07       Impact factor: 2.566

8.  Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy.

Authors:  A Oksanen; P Sipponen; R Karttunen; A Miettinen; L Veijola; S Sarna; H Rautelin
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

9.  Stomach cancer after partial gastrectomy for benign ulcer disease.

Authors:  G Lundegårdh; H O Adami; C Helmick; M Zack; O Meirik
Journal:  N Engl J Med       Date:  1988-07-28       Impact factor: 91.245

10.  Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.

Authors:  J Koskenpato; M Färkkilä; P Sipponen
Journal:  Scand J Gastroenterol       Date:  2002-07       Impact factor: 2.423

View more
  6 in total

Review 1.  Personalizing protein nourishment.

Authors:  David C Dallas; Megan R Sanctuary; Yunyao Qu; Shabnam Haghighat Khajavi; Alexandria E Van Zandt; Melissa Dyandra; Steven A Frese; Daniela Barile; J Bruce German
Journal:  Crit Rev Food Sci Nutr       Date:  2017-10-13       Impact factor: 11.176

2.  The Sleeping Remnant. Effect of Roux-En-Y Gastric Bypass on Plasma Levels of Gastric Biomarkers in Morbidly Obese Women: A Prospective Longitudinal Study.

Authors:  Federico Marchesi; Francesco Tartamella; Giuseppina De Sario; Clarissa Forlini; Alberta Caleffi; Matteo Riccò; Francesco Di Mario
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

3.  Increased GLP2R expression in gastric chief cells of patients with severe obesity regardless of diabetes status.

Authors:  F Li; L Lu; Y Peng; Y Zhang; J Gao; D Zhou; D Zhou; H Sheng; S Qu
Journal:  Int J Obes (Lond)       Date:  2017-03-24       Impact factor: 5.095

4.  Nutritional profile of patients before and after Roux-en-Y gastric bypass: 3-year follow-up.

Authors:  Carina Andriatta Blume; Carla Cristina Boni; Daniela Schaan Casagrande; Jacqueline Rizzolli; Alexandre Vontobel Padoin; Cláudio Corá Mottin
Journal:  Obes Surg       Date:  2012-11       Impact factor: 4.129

5.  The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones.

Authors:  Joshua R Shak; Jatin Roper; Guillermo I Perez-Perez; Chi-hong Tseng; Fritz Francois; Zoi Gamagaris; Carlie Patterson; Elizabeth Weinshel; George A Fielding; Christine Ren; Martin J Blaser
Journal:  Obes Surg       Date:  2008-04-12       Impact factor: 4.129

6.  Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality?

Authors:  Magnus Sundbom; Camilla Holdstock; Britt Eden Engström; F Anders Karlsson
Journal:  Obes Surg       Date:  2007-03       Impact factor: 3.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.